HTG Molecular Diagnostics announced it will host its next HTG Therapeutics key opinion leader webinar: "The Role of RNA Profiling in Drug Discovery and Analysis", on Tuesday, December 13, 2022 at 11:00 am Eastern Standard Time. This latest webinar features a presentation from KOL, Dr. Robert Spitale, PhD, from the University of California – Irvine, discussing the use of RNA profiling in the drug discovery process to better uncover mechanism of action and refine the drug screening processes. Additionally, the HTG Therapeutics team will present results from the application of its transcriptome-informed drug discovery process. Specifically, differential regulation of the ferroptosis pathway by structurally similar compounds that target mTOR will be offered as an example of how RNA profiling can aid in understanding post-target engagement consequences and expand our understanding of the biological implications of compound treatment.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HTGM:
- HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series
- HTG Molecular Diagnostics Reports Third Quarter 2022 Results
- HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery
